SUZHOU, China and GEMBLOUX, Belgium

中国苏州和比利时让布卢

,

，

May 18, 2026

2026年5月18日

/PRNewswire/ --

/PRNewswire/ --

Full-Life Technologies (

全生命技术公司 (

'

'

Full-Life

富勒生命

'

'

, the

，这个

'

'

Company

公司

'

'

),

),

a fully-integrated global radiotherapeutics company, today announced the completion of a US$150 million financing package, comprised of approximately US$110 million in Series D equity and US$40 million in debt financing. Vivo Capital led the financing, joined by Full-Life's strategic partner

一家完全整合的全球放射治疗公司，今天宣布完成了1.5亿美元的融资计划，其中包括约1.1亿美元的D轮股权融资和4000万美元的债务融资。Vivo Capital领投，Full-Life的战略合作伙伴也参与其中。

SK Biopharmaceuticals Co., Ltd. and Chengwei Capital, HSG, Junson Capital, Yunion, Plaisance, Sky9 Capital, TSG Capital

SK生物制药有限公司、成伟资本、HSG、君盛资本、优联资本、普莱桑斯、Sky9资本、TSG资本

, as well as other renowned shareholders.

以及其它知名股东。

Proceeds from the Series D round will be used to advance the Company's clinical stage assets, including potential

D轮融资的收益将用于推进公司的临床阶段资产，包括潜在的

best-in-class

一流的

[225Ac]-FL-020 for prostate cancer and potential

用于前列腺癌的[225Ac]-FL-020及其潜力

first-in-class

首创的

[225Ac]-FL-261 for multiple solid tumor indications. By year-end 2026, Full-Life expects to have three differentiated clinical stage programs, all of which emerged from its UniRDC™ discovery platform. Proceeds will also facilitate the initiation of GMP-grade 225Ac manufacturing at the Company's state-of-the-art facility in Belgium.

[225Ac]-FL-261用于多种实体瘤适应症。到2026年底，Full-Life预计将会拥有三个差异化的临床阶段项目，这些项目均源自其UniRDC™发现平台。所得资金还将推动公司在比利时的先进设施中启动GMP级225Ac的生产。

Having isotope supply and manufacture under its complete control is a significant strategic advantage in advancing radiotherapeutics rapidly through clinical development..

完全掌控同位素供应和生产，在通过临床开发快速推进放射治疗方面是一个重要的战略优势。

'Full-Life is distinguished not only by their scientific vision, but their ability to translate it into tangible clinical and operational milestones at a global scale,'

“Full-Life不仅以其科学视野著称，还因其能够将科学视野转化为全球范围内的临床和运营里程碑而闻名，”

said Hao Dong, Managing Director at Vivo Capital.

Vivo Capital的董事总经理董浩说。

'We are impressed by their early discovery efficiency, the strong emerging data from their lead program, and the accelerated progress of their manufacturing facility in Belgium. Leading this Series D financing reflects our conviction that Full-Life is transitioning from a platform innovator to a fully integrated radiopharmaceutical company, and we are excited to support their next phase of value creation.'  .

“我们对他们早期的发现效率、其主导项目中涌现的强有力数据以及他们在比利时的制造工厂的加速进展印象深刻。领导这次D轮融资反映了我们对Full-Life正在从一个平台创新者转型为一家完全整合的放射性药物公司的信心，我们非常高兴能够支持他们下一阶段的价值创造。”

'This financing reflects the significant value we have created over the past four years, evolving from a platform builder to a clinical-stage company,'

“这笔融资反映了我们在过去四年中创造的巨大价值，从一个平台构建者发展为一家临床阶段的公司，”

said Julie Wu, President and Chief Financial Officer of Full-Life.

富勒生命科技总裁兼首席财务官吴茱莉表示。

'With the strong momentum from our lead asset, and the rapid advancement of our pipeline assets, this funding will accelerate our transition toward late-stage development and ensure our Belgium GMP facility is fully operational to support global 225Ac commercial supply.'

“凭借我们领先资产的强大动力，以及我们渠道资产的快速推进，这笔资金将加速我们向后期开发的过渡，并确保我们在比利时的GMP设施全面投入运营，以支持全球225Ac的商业供应。”

With completion of this round, Full-Life has secured nearly US$350 million funding since its inception in 2021, including equity financing and debt financing.

随着本轮融资的完成，自2021年成立以来，辐联医药已获得近3.5亿美元的融资，包括股权融资和债务融资。

About Vivo Capital

关于维梧资本

Founded in 1996, Vivo Capital is a leading global healthcare investment firm with a multi-strategy platform spanning venture capital, private equity, and public markets. The firm manages over $7.0 billion across 16 USD and RMB funds and has invested in over 460 companies worldwide. Vivo Capital focuses exclusively on the healthcare sector, including biotechnology, pharmaceuticals, medical devices, and pharma services, with an emphasis on the world's largest and fastest-growing markets.

维梧资本（Vivo Capital）成立于1996年，是一家领先的全球医疗保健投资公司，拥有多策略平台，涵盖风险投资、私募股权和公开市场。该公司通过16只美元和人民币基金管理着超过70亿美元的资产，并已在全球范围内投资了460多家公司。维梧资本专注于医疗保健领域，包括生物技术、制药、医疗器械和医药服务，重点关注全球最大和增长最快的市场。

The firm is differentiated by its 'Ecosystem Strategy,' leveraging deep industry networks and operational capabilities to deliver strategic support beyond capital. Headquartered in Palo Alto, California, Vivo Capital has offices in Beijing, Shanghai, Hong Kong, Taipei, and Singapore, supported by a global team of over 70 professionals..

公司通过“生态系统战略”实现差异化，利用深厚的行业网络和运营能力，提供超越资本的战略支持。维梧资本总部位于加利福尼亚州帕洛阿尔托，在北京、上海、香港、台北和新加坡设有办事处，由一支超过70名专业人士的全球团队提供支持。

About Full-Life Technologies

关于全生命技术

Full-Life Technologies ('Full-Life') is a privately held, fully-integrated clinical-stage global radiotherapeutics company with operations worldwide. Our mission is to deliver the power of radiotherapy to cancer patients worldwide by owning the entire value chain for radiopharmaceutical research & development including production & commercialization.

全力科技（“Full-Life”）是一家私人控股的、完全整合的临床阶段全球放射治疗公司，在全球范围内开展业务。我们的使命是通过拥有放射性药物研发（包括生产和商业化）的整个价值链，为全球癌症患者提供放射治疗的力量。

By combining advanced manufacturing capabilities, biological insights and clinical efficiency, the Company endeavors to tackle fundamental challenges affecting radiopharmaceuticals today by pioneering innovative research that will shape the treatments of tomorrow. We are comprised of a team of fast-moving entrepreneurs and seasoned scientists with a proven history of success in the life sciences and unwavering dedication to patients worldwide.

通过结合先进的制造能力、生物学洞察和临床效率，公司致力于通过开创性的创新研究解决当今影响放射性药物的基本挑战，这将塑造未来的治疗方式。我们由一群快速行动的企业家和经验丰富的科学家组成，他们在生命科学领域有着成功的历史，并且始终如一地致力于为全球患者服务。

Learn more at: .

了解更多，请访问：。

https://www.full-life.com/

https://www.full-life.com/

SOURCE Full-Life Technologies

来源：Full-Life Technologies

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示